


# ASAFO & CO.: MCP IN STRATEGIC INVESTMENT AGREEMENT WITH LAPROPHAN

*Posted on 27 February 2023*



**Categories:** [Capital Markets](#), [Healthcare](#), [Pharma & Life Sciences](#), [Other](#)

**Tags:** [Asafo & Co.](#), [dx1](#), [Martin Van Box Som](#), [Patrick Larrivé](#)



[Asafo & Co.](#) provided advisory services to Mediterrania Capital Partners ('MCP') as it spearheaded a consortium to execute a strategic investment agreement with Laprophan, a prominent pharmaceuticals entity in Morocco.

MCP, a private equity firm with a focus on growth investments in small and mid-size African companies, led the consortium which included DEG, FMO, and Proparco. The agreement saw the consortium acquire a minority stake in Laprophan through a MDH 750 million capital increase.

The transaction is pending the approval of the Moroccan Competition Council. Laprophan is set to leverage the capital increase to accelerate its growth, increase its dominance in the local market, and expand its reach to international markets.

Asafo & Co. advised MCP on both the investment in Laprophan and the co-investment arrangements with the other consortium members. The Asafo & Co. team advising MCP was led by partner **Patrick Larrivé** (pictured) who was assisted by associate **Martin Van Box Som**.